These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease. Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850 [TBL] [Abstract][Full Text] [Related]
13. Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients. Ros-Castelló V; Natera-Villalba E; Gómez-López A; Sánchez-Sánchez A; Chico-García JL; García-Madrona S; Vera-Lechuga R; Matute-Lozano C; de Felipe Mimbrera A; Cruz-Culebras A; Alonso-Canovas A; Masjuan J Cerebrovasc Dis Extra; 2020; 10(3):166-173. PubMed ID: 33176324 [TBL] [Abstract][Full Text] [Related]
14. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill. Sanz G; Fuster V Mt Sinai J Med; 2012; 79(6):683-8. PubMed ID: 23239207 [TBL] [Abstract][Full Text] [Related]
15. The cardiovascular polypill: clinical data and ongoing studies. Castellano JM; Bueno H; Fuster V Int J Cardiol; 2015 Dec; 201 Suppl 1():S8-14. PubMed ID: 26747391 [TBL] [Abstract][Full Text] [Related]
16. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054 [TBL] [Abstract][Full Text] [Related]
17. Update to the Consensus Document on Clinical Use of the Polypill: New Dose Containing Atorvastatin 40 mg. González-Juanatey JR Rev Esp Cardiol (Engl Ed); 2018 Jul; 71(7):595-596. PubMed ID: 29752030 [No Abstract] [Full Text] [Related]
18. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial. Ostovaneh MR; Poustchi H; Hemming K; Marjani H; Pourshams A; Nateghi A; Majed M; Navabakhsh B; Khoshnia M; Jaafari E; Mohammadifard N; Malekzadeh F; Merat S; Sadeghi M; Naemi M; Etemadi A; Thomas GN; Sarrafzadegan N; Cheng KK; Marshall T; Malekzadeh R Eur J Prev Cardiol; 2015 Dec; 22(12):1609-17. PubMed ID: 25230980 [TBL] [Abstract][Full Text] [Related]
19. Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. Masjuan J; Gállego J; Aguilera JM; Arenillas JF; Castellanos M; Díaz F; Portilla JC; Purroy F Neurologia (Engl Ed); 2021; 36(1):1-8. PubMed ID: 29325730 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain. González-Domínguez A; Durán A; Hidalgo-Vega Á; Barrios V Rev Clin Esp (Barc); 2023; 223(7):414-422. PubMed ID: 37352973 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]